Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Operating Expenses (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Other Operating Expenses data on record, last reported at $28.3 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 24.07% year-over-year to $28.3 million; the TTM value through Dec 2025 reached $100.2 million, up 22.78%, while the annual FY2025 figure was $100.2 million, 22.78% up from the prior year.
  • Other Operating Expenses reached $28.3 million in Q4 2025 per MIRM's latest filing, up from $25.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $28.3 million in Q4 2025 and bottomed at $1.9 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $14.3 million, with a median of $17.8 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 456.74% in 2023, then fell 8.95% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $1.9 million in 2021, then soared by 136.15% to $4.5 million in 2022, then surged by 456.74% to $25.0 million in 2023, then fell by 8.95% to $22.8 million in 2024, then grew by 24.07% to $28.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $28.3 million in Q4 2025, $25.5 million in Q3 2025, and $23.4 million in Q2 2025.